Technical Analysis for BCYC - Bicycle Therapeutics plc

Grade Last Price % Change Price Change
grade B 13.1 5.65% 0.70
BCYC closed up 5.65 percent on Friday, June 14, 2019, on 76 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A N/A Up
See historical BCYC trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
Up 3 Days in a Row Strength 0.00%
Narrow Range Bar Range Contraction 5.65%
NR7 Range Contraction 5.65%
Hot IPO Pullback Bullish Swing Setup 9.81%
Inside Day Range Contraction 9.81%
Doji - Bearish? Reversal 10.08%
Outside Day Range Expansion 10.08%
NR7 Range Contraction 10.08%
NR7-2 Range Contraction 10.08%

Older signals for BCYC ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in preclinical studies targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage, as well as systemically-delivered activators. In addition, it is developing THR-149, a key immune cell co-stimulatory molecule that is in Phase I clinical trials. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, hematology, ophthalmology, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; and research collaboration agreement with Bioverativ Inc., AstraZeneca AB, and Oxurion NV. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Medicine Health Biopharmaceutical Life Sciences Diseases Immunology Oncology Tumors Astrazeneca Immune Checkpoint
Is BCYC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 13.75
52 Week Low 10.6
Average Volume 86,344
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 0.0
10-Day Moving Average 11.88
Average True Range 0.9982
ADX 0.0
+DI 10.3357
-DI 13.8837
Chandelier Exit (Long, 3 ATRs ) 10.7554
Chandelier Exit (Short, 3 ATRs ) 13.5946
Upper Bollinger Band 0.0
Lower Bollinger Band 0.0
Percent B (%b) 0.0
BandWidth 0.0
MACD Line 0.1458
MACD Signal Line 0.0371
MACD Histogram 0.1087
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.30
Resistance 3 (R3) 14.20 13.70 14.10
Resistance 2 (R2) 13.70 13.39 13.75 14.03
Resistance 1 (R1) 13.40 13.21 13.55 13.50 13.97
Pivot Point 12.90 12.90 12.98 12.95 12.90
Support 1 (S1) 12.60 12.59 12.75 12.70 12.23
Support 2 (S2) 12.10 12.41 12.15 12.17
Support 3 (S3) 11.80 12.10 12.10
Support 4 (S4) 11.90